Antibiotics, Antitubercular
"Antibiotics, Antitubercular" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic.
| Descriptor ID |
D000904
|
| MeSH Number(s) |
D27.505.954.122.085.255.135
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibiotics, Antitubercular".
Below are MeSH descriptors whose meaning is more specific than "Antibiotics, Antitubercular".
This graph shows the total number of publications written about "Antibiotics, Antitubercular" by people in this website by year, and whether "Antibiotics, Antitubercular" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 4 | 6 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 4 | 0 | 4 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibiotics, Antitubercular" by people in Profiles.
-
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis. Lancet Infect Dis. 2023 07; 23(7):778-780.
-
Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis. Lancet Infect Dis. 2022 04; 22(4):507-518.
-
Rifampicin-resistant TB: discordance between Xpert® MTB/RIF and MTBDRplus results. Int J Tuberc Lung Dis. 2021 10 01; 25(10):832-838.
-
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 05 06; 384(18):1705-1718.
-
Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa. Int J Tuberc Lung Dis. 2021 02 01; 25(2):134-141.
-
Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impact. J Antimicrob Chemother. 2020 05 01; 75(5):1123-1129.
-
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis. AIDS. 2019 11 15; 33(14):2197-2203.
-
Discordant rifampicin susceptibility results are associated with Xpert® MTB/RIF probe B and probe binding delay. Int J Tuberc Lung Dis. 2019 03 01; 23(3):358-362.
-
Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa. BMC Health Serv Res. 2018 Dec 17; 18(1):973.
-
The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis. J Antimicrob Chemother. 2018 10 01; 73(10):2667-2674.